FCCC LOGO Faculty Publications
Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features
J Urol. 2016 Apr;195(4 Pt 1) :852-8
PMID: 26602888    PMCID: PMC4871784    URL: https://www.ncbi.nlm.nih.gov/pubmed/26602888
Back to previous list
Abstract
PURPOSE: Sarcomatoid changes in renal cell carcinoma are associated with a poor prognosis. The identification of genetic alterations that drive this aggressive phenotype could aid in the development of more effective targeted therapies. In this study we aimed to pinpoint unique copy number alterations in sarcomatoid renal cell carcinoma compared to classical renal cell carcinoma subtypes. MATERIALS AND METHODS: Genomic copy number analysis was performed using single nucleotide polymorphism based microarrays on tissue extracted from the tumors of 81 patients who underwent renal mass excision, including 17 with sarcomatoid renal cell carcinoma. RESULTS: Sarcomatoid renal cell carcinoma showed a significantly higher number of copy number alterations than clear cell, papillary and chromophobe renal cell carcinoma (mean 18.0 vs 5.8, 6.5 and 7.2, respectively, p <0.0001). Copy number losses of chromosome arms 9q, 15q, 18p/q and 22q, and gains of 1q and 8q occurred in a significantly higher proportion of sarcomatoid renal cell carcinomas than in the other 3 histologies. Patients with sarcomatoid renal cell carcinoma demonstrated significantly worse overall survival compared to those without that condition on Kaplan-Meier analysis (p = 0.0001). Patients with 9 or more copy number alterations also demonstrated significantly worse overall survival than those with fewer than 9 copy number alterations (p = 0.004). CONCLUSIONS: Sarcomatoid changes in renal cell carcinoma are associated with a high rate of chromosomal imbalances with losses of 9q, 15q, 18p/q and 22q, and gains of 1q and 8q occurring at significantly higher frequencies in comparison to nonsarcomatoid renal cell carcinoma. Identifying candidate driver genes or tumor suppressor loci in these chromosomal regions may help identify targets for future therapies.
Notes
Ito, Timothy Pei, Jianming Dulaimi, Essel Menges, Craig Abbosh, Philip H Smaldone, Marc C Chen, David Y T Greenberg, Richard E Kutikov, Alexander Viterbo, Rosalia Uzzo, Robert G Testa, Joseph R eng P30 CA006927/CA/NCI NIH HHS/ 2015/11/26 06:00 J Urol. 2016 Apr;195(4P1):852-8. doi: 10.1016/j.juro.2015.10.180. Epub 2015 Nov 18.